XLV Health Care Select Sector SPDR Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
16:00
Jun 03
Jun 03
The tweet provides a detailed sector and factor rotation analysis with commodity reflation themes but contains no explicit first-person position language or forward directional call, only factual market observations.
19:26
May 30
May 30
The author notes insider buying in biotech and healthcare plays, aligning with a defensive rotation thesis, but does not state a personal position.
09:10
May 29
May 29
Korean pharma/biotech undervalued, catalysts ahead.
Korean pharma and biotech stocks are similarly undervalued based on historical PER, with earnings on an upward trend. The sector has been suppressed by high bond yields, but upcoming medical conferences in late May/June 2025 and potential yield stabilization should unlock value. Focus on profitable companies with visible earnings.
HIGH
11:30
May 28
May 28
Biotech sector showing relative strength.
The Korean pharma/biotech sector has underperformed due to failed trials and trust issues, but most bad news is priced in. Recent relative strength against the KOSDAQ index, coupled with ongoing FDA approvals and occasional stock surges (Hanall Biopharma, DND Pharmatech), suggests a bottoming process. He holds 10% and is considering adding on further strength.
MED
20:59
May 26
May 26
Higher rates remain a structural headwind for defensive healthcare and staples sectors; even in a broadly bullish tape, rate pressure makes XLV a relative underperformer with bearish near-term bias.
MED
23:04
May 22
May 22
Tech and healthcare for 401k.
For 401(k) investors seeking long-term growth, technology is the first sector and healthcare is the second; these are the only sectors worth considering.
MED
22:56
May 22
May 22
Long healthcare as defensive AI alternative.
Healthcare is a defensive sector with demand outside of AI, has been oversold, and provides diversification against the concentrated tech rally.
MED
22:39
May 22
May 22
New pandemic, long ZM and pharma
If a mutated Ebola strain causes another pandemic, long Zoom (ZM) and big pharma (XLV). The COVID playbook repeats.
MED
15:49
May 18
May 18
Long healthcare, trim tech.
Investors should trim positions in high-flying tech/AI names and redeploy capital into the healthcare sector, which is poised to benefit from AI adoption but has not yet run up as much.
MED
20:03
May 12
May 12
The tweet provides a detailed technical and cross-asset analysis highlighting overbought conditions, defensive rotation, and rising VIX that suggest a cautious or bearish outlook without explicitly stating the author's own directional trade.
14:28
May 12
May 12
The tweet reports a defensive rotation into healthcare and staples with tech selling off, but cross-asset oil strength and dollar gains suggest stagflationary pressures rather than pure risk-off sentiment.
LOW
19:49
May 11
May 11
The tweet provides a detailed factual report on sector rotations and factor performance with energy and materials leading cyclicals while defensives lag, but offers no forward-looking opinion or trade recommendation from the author.
HIGH
06:05
May 11
May 11
Favor US health care
US health care sector has been underperforming relative to tech, making it a good area to invest in as it offers value and potential catch-up.
MED
00:30
May 10
May 10
The tweet reports that defensive sectors like healthcare, consumer staples, and utilities have reached historically low weightings in the S&P 500 while tech dominates, but it offers no explicit forward-looking forecast.
HIGH
17:39
May 08
May 08
The author suggests SOXX is a strong investment while predicting that an FDA regulatory change would be the most bullish catalyst for healthcare investors since September 2025, boosting XLV.
HIGH
07:00
May 07
May 07
Pharma/biosimilars are buys.
Pharmaceuticals (and biosimilars) are undervalued relative to earnings and have been pressured by bond yields. Within biotech, only stable earners like pharma and biosimilars are preferred. The sector offers a rebound play once bond yields stabilize.
MED
01:53
May 07
May 07
Buy Korean biotech ETFs on weakness.
The biotech sector is currently underowned as money flows to AI and semiconductors, but fundamentals are strong due to a patent cliff from 2025 to 2028 that will drive demand for biosimilars and technology transfers. Current valuations are low, making this a buying opportunity. The speaker expects eventual capital rotation into biotech and recommends gradual accumulation of Korean biotech ETFs.
HIGH
07:00
May 06
May 06
Pharma/biotech to rally on rate cuts.
The Korean pharma/biotech sector is underperforming but presents a long-term opportunity. When the new Fed chair (Kevin Warsh) signals rate cuts, the sector could rally quickly. PharmaResearch specifically is expected to move higher.
MED
14:57
May 05
May 05
Healthcare spending as % of GDP is in a long‑term uptrend (10%→21%), but XLV’s S&P weight dropped from 16% to 10%, near 1994 lows. When the GDP share inflects up, the market‑cap share has historically surged. Maximum pessimism now resembles the 1994‑1996 pharma rally catalyst. Buying the sector ETF XLV bets on mean reversion as aging demographics and policy fears fade, capturing the entire cheap sector. Renewed price‑control legislation (e.g., IRA expansion), recession cutting healthcare spending, or a tech/AI bubble stealing capital.
HIGH
14:53
Apr 23
Apr 23
Health care cheap with secular growth.
The health care sector is the only sector that can compete with technology in terms of secular growth. It is historically cheap versus its average due to regulatory overhang and negative sentiment, presenting a valuation opportunity.
MED
20:50
Apr 22
Apr 22
Consumer and healthcare sectors exposed to SNAP/Medicaid changes.
Consumer and healthcare sectors are exposed to potential changes in SNAP and Medicaid programs depending on the midterm election outcome; a unified Democratic majority could limit downside impact by delaying or softening these changes.
HIGH
22:15
Apr 21
Apr 21
Favor tech, communications, financials, health care, utilities.
Technology, tech hardware, all of tech and most of communications are a place to be because they are driving earnings growth and are less exposed to oil and interest rate risks. Financials, health care, and utilities also have upside or are least exposed to these risks.
HIGH
20:26
Apr 21
Apr 21
Favor defensive secular growth in staples and healthcare.
Investors should be defensive but focus on growth companies with secular demand that are not dependent on the consumer or industrial production cycles, specifically highlighting consumer staples and health care as necessary areas to be in, with Johnson & Johnson as an example.
MED
16:15
Apr 19
Apr 19
Avoid bonds, utilities, healthcare in inflation.
In inflationary QE environment, long-term fixed income loses purchasing power. Utilities and healthcare are regulated and cannot raise prices enough, so they underperform. Investors should avoid long-term bonds, utilities sector, and healthcare sector.
HIGH
21:50
Apr 17
Apr 17
Buy financials, industrials, healthcare, energy.
During market corrections, sectors like financials, industrials, healthcare, and energy present undervalued buying opportunities to add to portfolios opportunistically, as they offer more attractive valuations compared to fully valued areas.
HIGH
00:51
Apr 17
Apr 17
Bullish on U.S. pharmaceutical companies.
Tariffs and policies are encouraging pharmaceutical companies to invest and manufacture in the U.S., bringing in levels of investment never seen before and supporting sector growth.
MED
16:37
Apr 16
Apr 16
Upgraded health care sector.
UBS has upgraded health care as a defensive area in response to market uncertainties.
MED
11:23
Apr 15
Apr 15
Buy healthcare and biotech for AI benefits.
Healthcare and biotech are overlooked beneficiaries of AI, which can accelerate drug development with more accurate results, making them attractive investments compared to tech.
MED
10:36
Apr 15
Apr 15
Overweight defensive health care and utilities.
In volatile and uncertain markets, they have adopted a more defensive posture and are slightly overweight the health care and utilities sectors.
MED
22:21
Apr 10
Apr 10
Healthcare benefits from demographic trends.
Demographics are on the side of the healthcare industry, making it a favorable sector for investment due to aging population trends.
LOW
About XLV Analyst Coverage
Buzzberg tracks XLV (Health Care Select Sector SPDR) across 27 sources. 48 bullish vs 2 bearish calls from 77 analysts. Sentiment: predominantly bullish (49%). 94 total trade ideas tracked.